Advances in GLP-1 receptor agonists for pain treatment and their future potential

The Journal of Headache and Pain, Journal Year: 2025, Volume and Issue: 26(1)

Published: Feb. 27, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show substantial efficacy in regulating blood glucose levels and lipid metabolism, initially as an effective treatment for diabetes mellitus. In recent years, GLP-1RAs have become a focal point the medical community due to their innovative mechanisms, robust therapeutic efficacy, expansive development prospects. Notably, benefit pain management through neuroprotective metabolic regulatory properties, such inhibiting inflammation responses oxidative stress, promoting β-endorphin release modulating several other crucial biological pathways. Hence hold promise repurposing treatments disorders. this narrative review, we thoroughly trace current preclinical clinical evidence of seven modalities, including inflammatory pain, osteoarthritis, visceral neuropathic diabetic neuropathy, cancer headache, support underlying mechanisms agents suffering. Despite these promising findings, further research is necessary establish long-term optimal dosing strategies, potential synergistic interactions with existing therapies. Future trials should aim distinguish direct analgesic effects from benefits explore broader applications conditions. The ongoing exploration new indications highlights transformative advancing across diverse fields.

Language: Английский

Neuroinflammation in diabetic peripheral neuropathy and therapeutic implications

Reviews in the Neurosciences, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Abstract Diabetic peripheral neuropathy (DPN) is a serious complication of diabetes mellitus, which common cause disability in individuals with mellitus. Multiple mechanisms may be involved the development DPN. Neuroinflammation critical factor contributing to nerve damage during diabetes. Inflammation can induce and long-term hyperglycemia also causes increased oxidative stress promotes release inflammatory cytokines. After reading through literature, association inflammation induction DPN was discussed review. induces conduction impairment. The neuropathic pain diabetes-induced closely associated response. Given important roles DPN, explicit elucidation neuroinflammation mellitus should hold potential for developing novel therapeutic strategies Experimental studies limited clinical trials support value anti-inflammatory reagents treating positive outcomes these investigations warrant further trials.

Language: Английский

Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors in Neuropathic Pain: Mechanisms and Clinical Implications

Biomolecules, Journal Year: 2025, Volume and Issue: 15(5), P. 622 - 622

Published: April 26, 2025

Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by the small intestine upon food intake. GLP-1 enhances insulin secretion, suppresses glucagon release, and promotes satiety, resulting in reduced consumption subsequent weight loss. Endogenous has very short half-life rapidly degraded enzyme dipeptidyl-peptidase-IV (DPP-4). To address this limitation, receptor agonists (GLP-1RAs) DPP-4 inhibitors (DPP-4is) were developed have demonstrated potency clinical practice. In recent years, GLP-1RA DPP4-i therapies are known to pleiotropic effects, such as reduction oxidative stress, autophagy regulation, metabolic reprogramming, enhancement of anti-inflammatory signaling, regulation gene expression, being neuroprotective. These effects imply therapeutic perspective for DPP-4i neuropathic pain treatment. Preclinical studies increasingly support hypothesis that these may alleviate targeting multiple mechanisms induce pain, inflammation, mitochondrial dysfunction. This review explores which GLP-1RAs DPP-4is pain. It also highlights current advancements incretin research, focusing on DPP-4-is

Language: Английский